Peptide Comparison
SurvodutidevsRetatrutide
Dual GLP-1/glucagon receptor agonist for obesity and metabolic liver disease
The world's first triple-action weight loss peptide that simultaneously activates three hormone receptors—GIP, GLP-1, and glucagon—delivering unprecedented weight loss results of up to 24% body weight in clinical trials.
At a Glance
Quick
comparison
Dose Range
Survodutide
2.4 mg–6 mg mg
Retatrutide
1–12 mg
Frequency
Survodutide
Once daily
Retatrutide
Once weekly
Administration
Survodutide
subcutaneous injection
Retatrutide
Subcutaneous injection
Cycle Length
Survodutide
Ongoing/indefinite
Retatrutide
12+ weeks
Onset Speed
Survodutide
Moderate (1-2 weeks)
Retatrutide
Moderate (1-2 weeks)
Evidence Level
Survodutide
Strong human trials (Phase 3 or FDA approved)
Retatrutide
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Weight Management
Metabolic Health
Blood Sugar Control
Weight Loss Power
Appetite Control
Technical Data
Compound
specifications
Survodutide
Molecular Formula
C192H289N47O61
Molecular Weight
4,231.6 Da
Half-Life
~7 days (enabling once-weekly dosing)
Bioavailability
Optimized for subcutaneous administration with C18 acylation
CAS Number
2805997-46-8
Retatrutide
Molecular Formula
C221H342N46O68
Molecular Weight
4731 g/mol
Half-Life
~6 days (allows once-weekly dosing)
Bioavailability
High via subcutaneous injection
CAS Number
2381089-83-2
Protocols
Dosing
tiers
Survodutide
Retatrutide
Applications
Best
suited for
Survodutide
Significant body weight reduction in obesity
Survodutide is particularly well-suited for individuals focused on significant body weight reduction in obesity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
MASH/NASH resolution and liver fibrosis improvement
Survodutide is particularly well-suited for individuals focused on mash/nash resolution and liver fibrosis improvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Type 2 diabetes management with concurrent weight loss goals
Survodutide is particularly well-suited for individuals focused on type 2 diabetes management with concurrent weight loss goals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Enhanced metabolic outcomes through dual receptor engagement
Survodutide is particularly well-suited for individuals focused on enhanced metabolic outcomes through dual receptor engagement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Retatrutide
Significant Obesity Management
If you need to lose a substantial amount of weight, retatrutide is showing unprecedented results. Phase 2 trials demonstrated average weight loss of 24% at the highest dose—that's nearly 60 pounds for someone weighing 250 lbs. No other medication has matched this.
Type 2 Diabetes with Obesity
Retatrutide tackles both problems at once. It dramatically improves blood sugar control (HbA1c reductions of up to 2%) while delivering major weight loss. The dual benefit makes it especially valuable for diabetics struggling with weight.
Metabolic Syndrome Warriors
If you're dealing with the cluster of issues that includes high blood sugar, excess belly fat, abnormal cholesterol, and high blood pressure, retatrutide's triple mechanism attacks multiple aspects of metabolic dysfunction simultaneously.
Fatty Liver Disease (MASLD)
Early research shows retatrutide may significantly reduce liver fat. For people with non-alcoholic fatty liver disease, this peptide offers hope through weight loss plus direct metabolic improvements that benefit liver health.
Safety Profile
Side
effects
Survodutide
Common
- Nausea
- Vomiting
- Diarrhea
- Decreased Appetite
Uncommon
- Constipation and Abdominal Pain
Serious
- Acute Pancreatitis
Retatrutide
Common
- Nausea
- Diarrhea
- Constipation
- Decreased appetite
Uncommon
- Increased heart rate
- Injection site reactions
Serious
- Pancreatitis
- Gallbladder problems
Research Status
Safety
& evidence
Survodutide
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
Research compound
Safety Overview
Survodutide data comes from Phase 2 obesity and MASH trials with dose-dependent gastrointestinal side effects (nausea up to 75% at highest doses, diarrhea, vomiting) that mirror GLP-1 receptor agonist class effects but occur with greater frequency due to additional glucagon receptor activation increasing energy expenditure. Pancreatitis risk exists as with all GLP-1 agonists—baseline lipase evaluation and patient education on warning signs (persistent upper abdominal pain) are essential. Medullary thyroid carcinoma risk, though theoretical based on GLP-1 class, contraindicates use in MEN 2 or personal thyroid cancer history.
Contraindications
- xPersonal or family history of medullary thyroid carcinoma (GLP-1 class warning)
- xMultiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- xKnown hypersensitivity to survodutide or excipients
- xHistory of pancreatitis (caution advised with GLP-1 receptor agonists)
Retatrutide
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Retatrutide has shown a generally favorable safety profile in Phase 1 and Phase 2 clinical trials involving over 600 participants. Most side effects are gastrointestinal and tend to improve over time. The medication appears well-tolerated when doses are increased gradually. No major safety signals have emerged, but larger Phase 3 trials are still ongoing.
Contraindications
- xPersonal or family history of medullary thyroid carcinoma (MTC)
- xMultiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- xPregnancy or planning to become pregnant
- xHistory of severe pancreatitis
- xKnown allergy to GLP-1 receptor agonists
Decision Guide
Which is
right for you?
Choose Survodutide if...
- Significant body weight reduction in obesity
- MASH/NASH resolution and liver fibrosis improvement
- Type 2 diabetes management with concurrent weight loss goals
- Enhanced metabolic outcomes through dual receptor engagement
Choose Retatrutide if...
- Significant weight loss
- Type 2 diabetes management
- Metabolic health improvement
- Body composition optimization